Introduction
The RATE-AF trial was designed to compare digoxin or beta-blockers for rate-control in patients with permanent atrial fibrillation (AF). The trial recruited 160 patients with AF between 2016 and 2018 who were randomly assigned to one of either digoxin or beta-blockers. The trial assessed the effect of treatment on a patients quality of life, the function of their heart, as well as changes to blood markers and the need for admission to hospital. The study has now finished recruiting and the publication of results can be found below
preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial
European Journal of Heart Failure / September 02, 2025
the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) randomised trial
Heart BMJ / March 26, 2025
Nature Medicine / July 15, 2024
Heart BMJ / March 10, 2021
The RATE-AF Randomized Clinical Trial
European Heart Journal / February 28, 2021
The American Journal of Cardiology / January 15, 2021
The RATE-AF Randomized Clinical Trial
Journal of the American Medical Association / December 22, 2020
Patient Focus Groups from the RATE-AF Trial
Cardiologia / August 28, 2020
An individual-patient data meta-analysis
The Lancet Digital Health / September 02, 2014
Our Most Recent Publications ...
Select a heading from our publications below to be redirected to the journal
Discover More ...
Use the links below to see tailored content for Healthcare Professionals and Patients, or find out more about results associated with the DaRe2THINK study